{"id":37554,"date":"2026-08-10T11:57:09","date_gmt":"2026-08-10T11:57:09","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=37554"},"modified":"2026-08-10T11:57:09","modified_gmt":"2026-08-10T11:57:09","slug":"innate-pharma-partners-with-sobi-on-lacutamab","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","title":{"rendered":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u30e9\u30af\u30bf\u30de\u30d6\u306b\u95a2\u3057\u3066\u30bd\u30d3\u3068\u63d0\u643a"},"content":{"rendered":"<p><a href=\"https:\/\/www.innate-pharma.com\/\">\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de<\/a> SA \u304a\u3088\u3073 Swedish Orphan Biovitrum AB (publ) (<a href=\"https:\/\/www.sobi.com\/en\">\u30bd\u30d3<\/a>\uff09\u306f\u672c\u65e5\u3001\u76ae\u819aT\u7d30\u80de\u30ea\u30f3\u30d1\u816b\uff08CTCL\uff09\u3092\u5bfe\u8c61\u3068\u3057\u305fTELLOMAK-3\u78ba\u8a8d\u7b2c3\u76f8\u8a66\u9a13\u306e\u958b\u59cb\u3092\u53ef\u80fd\u306b\u3059\u308b\u305f\u3081\u3001\u6226\u7565\u7684\u63d0\u643a\u3092\u7de0\u7d50\u3057\u305f\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u3053\u308c\u306f\u3001CTCL\u306e\u4e9c\u578b\u3067\u3042\u308b\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u30e9\u30af\u30bf\u30de\u30d6\u306e\u8fc5\u901f\u627f\u8a8d\u7533\u8acb\u306b\u5411\u3051\u305f\u91cd\u8981\u306a\u4e00\u6b69\u3068\u306a\u308a\u307e\u3059\u3002.<\/p>\n<p>\u672c\u5951\u7d04\u306b\u57fa\u3065\u304d\u3001\u30a4\u30cd\u30a4\u30c8\u793e\u306f\u76ae\u819aT\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u3092\u5bfe\u8c61\u3068\u3057\u305f\u7b2cIII\u76f8\u78ba\u8a8d\u8a66\u9a13\u300cTELLOMAK-3\u300d\u3092\u5b9f\u65bd\u3057\u3001\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u65e9\u671f\u627f\u8a8d\u7533\u8acb\u3092\u652f\u63f4\u3059\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002 \u8a08\u753b\u3055\u308c\u3066\u3044\u308bTELLOMAK-3\u8a66\u9a13\u306f\u3001\u305d\u306e\u5f8c\u3001\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u304a\u3088\u3073\u6700\u3082\u4e00\u822c\u7684\u306a\u4e9c\u578b\u3067\u3042\u308b\u83cc\u72b6\u606f\u8089\u816b\u306b\u3064\u3044\u3066\u3001\u4e3b\u8981\u306a\u7ba1\u8f44\u533a\u57df\u306b\u304a\u3051\u308b\u5b8c\u5168\u627f\u8a8d\u7533\u8acb\u3092\u88cf\u4ed8\u3051\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002Sobi\u793e\u306f\u3001\u65e9\u671f\u627f\u8a8d\u304c\u5f97\u3089\u308c\u305f\u5834\u5408\u3001\u30e9\u30af\u30bf\u30de\u30d6\u306e\u5168\u4e16\u754c\u306b\u304a\u3051\u308b\u72ec\u5360\u7684\u306a\u5546\u696d\u5316\u6a29\u3092\u53d6\u5f97\u3057\u3001\u7b2c3\u76f8\u8a66\u9a13\u3067\u826f\u597d\u306a\u7d50\u679c\u304c\u5f97\u3089\u308c\u305f\u5834\u5408\u306b\u306f\u3001\u5168\u4e16\u754c\u306b\u304a\u3051\u308b\u5b8c\u5168\u306a\u958b\u767a\u6a29\u3092\u5f15\u304d\u7d99\u3050\u8cc7\u683c\u3092\u5f97\u308b\u3053\u3068\u306b\u306a\u308a\u307e\u3059\u3002 \u672c\u53d6\u5f15\u306e\u5b8c\u4e86\u306f\u3001\u53d6\u5f15\u306b\u95a2\u9023\u3059\u308b\u72ec\u5360\u7981\u6b62\u6cd5\u4e0a\u306e\u627f\u8a8d\u306e\u53d6\u5f97\u3092\u542b\u3080\u3001\u5b8c\u4e86\u6761\u4ef6\u3092\u6e80\u305f\u3059\u3053\u3068\u3092\u6761\u4ef6\u3068\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n<h3>\u30e9\u30af\u30bf\u30de\u30d6\u306b\u3064\u3044\u3066<\/h3>\n<p>\u30e9\u30af\u30bf\u30de\u30d6\u306f\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30fb\u30a4\u30f3\u30fb\u30af\u30e9\u30b9\u306e\u6297KIR3DL2\u6297\u4f53\u3067\u3042\u308a\u3001\u73fe\u5728\u3001\u76ae\u819aT\u7d30\u80de\u30ea\u30f3\u30d1\u816b\uff08CTCL\uff09\u3092\u5bfe\u8c61\u306b\u958b\u767a\u304c\u9032\u3081\u3089\u308c\u3066\u3044\u307e\u3059\u3002 CTCL\u306f\u3001\u5e0c\u5c11\u306a\u975e\u30db\u30b8\u30ad\u30f3\u30ea\u30f3\u30d1\u816b\u306e\u4e00\u7fa4\u3067\u3042\u308a\u3001\u305d\u306e\u4e2d\u306b\u306f\u3001\u5e0c\u5c11\u304b\u3064\u4fb5\u8972\u6027\u306e\u9ad8\u3044\u767d\u8840\u75c5\u578b\u3067\u3042\u308b\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u3084\u3001CTCL\u306e\u4e2d\u3067\u6700\u3082\u4e00\u822c\u7684\u306a\u4e9c\u578b\u3067\u3042\u308b\u83cc\u72b6\u8089\u82bd\u816b\u306a\u3069\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p>\n<h4>\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a <a class=\"p-url\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/em-systems-and-good-cycle-systems-merge-systems\/\" rel=\"bookmark\">EM Systems\u793e\u3068Good Cycle Systems\u793e\u304c\u5408\u4f75\u3057\u307e\u3057\u305f<\/a><\/h4>\n<p>\u672c\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3001FDA\u304b\u3089\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3001EMA\u304b\u3089\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308bPRIME\u6307\u5b9a\u3001\u7c73\u56fd\u304a\u3088\u3073EU\u306e\u4e21\u65b9\u304b\u3089CTCL\u306b\u5bfe\u3059\u308b\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3001\u306a\u3089\u3073\u306bFDA\u304b\u3089\u518d\u767a\u307e\u305f\u306f\u96e3\u6cbb\u6027\u306e\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308b\u30d6\u30ec\u30fc\u30af\u30b9\u30eb\u30fc\u30fb\u30bb\u30e9\u30d4\u30fc\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002 \u672c\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u3001\u5c11\u306a\u304f\u3068\u30821\u56de\u306e\u5168\u8eab\u7642\u6cd5\u3067\u594f\u52b9\u304c\u5f97\u3089\u308c\u306a\u304b\u3063\u305f\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u304a\u3088\u3073\u83cc\u72b6\u606f\u8089\u816b\u306e\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u3001\u975e\u76f2\u691c\u30fb\u591a\u65bd\u8a2d\u5171\u540c\u30fb\u7121\u4f5c\u70ba\u5316\u8a66\u9a13\u3067\u3042\u308b\u7b2cIII\u76f8\u4e3b\u8981\u8a66\u9a13\u300cTELLOMAK-3\u300d\u306b\u5411\u3051\u3066\u9032\u5c55\u3057\u3066\u3044\u307e\u3059\u3002 \u672c\u8a66\u9a13\u306b\u306f\u3001\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u304a\u3051\u308b\u78ba\u8a8d\u30b3\u30db\u30fc\u30c8\u304c\u542b\u307e\u308c\u3066\u304a\u308a\u3001\u3053\u308c\u306f\u6f5c\u5728\u7684\u306a\u65e9\u671f\u627f\u8a8d\u304a\u3088\u3073\u8a66\u9a13\u5b8c\u4e86\u5f8c\u306e\u30bb\u30b6\u30ea\u30fc\u75c7\u5019\u7fa4\u306b\u5bfe\u3059\u308b\u5b8c\u5168\u627f\u8a8d\u3092\u88cf\u4ed8\u3051\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u83cc\u72b6\u771f\u83cc\u75c7\u306b\u304a\u3051\u308b\u767b\u9332\u30b3\u30db\u30fc\u30c8\u3082\u542b\u307e\u308c\u3066\u304a\u308a\u3001\u3053\u308c\u306f\u5b8c\u5168\u627f\u8a8d\u3092\u88cf\u4ed8\u3051\u308b\u3053\u3068\u3092\u76ee\u7684\u3068\u3057\u3066\u304a\u308a\u3001\u7121\u5897\u60aa\u751f\u5b58\u671f\u9593\uff08PFS\uff09\u3092\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3068\u3057\u3066\u3044\u307e\u3059\u3002.<\/p>\n<p><strong>\u51fa\u5178\uff1a <a href=\"https:\/\/www.businesswire.com\/\" target=\"_blank\" rel=\"noopener\">\u30d3\u30b8\u30cd\u30b9\u30fb\u30ef\u30a4\u30e4<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>Innate Pharma SA\u00a0 and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in S\u00e9zary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in S\u00e9zary syndrome. The planned TELLOMAK-3 study will subsequently support applications for full approvals in key jurisdictions in S\u00e9zary syndrome and mycosis fungoides, the most common subtype. Sobi will receive exclusive global rights to commercialize lacutamab upon [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":37592,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237,182],"tags":[14505,14509,14507,14506,14508],"ppma_author":[205],"class_list":["post-37554","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-international","category-news","category-pharma","tag-fda","tag-innate-pharma","tag-lacutamab","tag-sezary-syndrome","tag-sobi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Licenses Lacutamab to Sobi<\/title>\n<meta name=\"description\" content=\"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Licenses Lacutamab to Sobi\" \/>\n<meta property=\"og:description\" content=\"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-10T11:57:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NewsDesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"NewsDesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u30bd\u30d3\u793e\u306b\u30e9\u30af\u30bf\u30de\u30d6\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","description":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u306f\u3001T\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u306e\u6cbb\u7642\u85ac\u300c\u30e9\u30af\u30bf\u30de\u30d6\u300d\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e\u3092\u3081\u3050\u308a\u3001\u30bd\u30d3\u793e\u3068\u6226\u7565\u7684\u63d0\u643a\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","og_locale":"ja_JP","og_type":"article","og_title":"Innate Pharma Licenses Lacutamab to Sobi","og_description":"Innate Pharma enters a strategic partnership with Sobi to license Lacutamab for the treatment of T-cell lymphoma.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","og_site_name":"itbusinesstoday","article_published_time":"2026-08-10T11:57:09+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","type":"image\/webp"}],"author":"NewsDesk","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"NewsDesk","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"},"author":{"name":"NewsDesk","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812"},"headline":"Innate Pharma Partners With Sobi on Lacutamab","datePublished":"2026-08-10T11:57:09+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"},"wordCount":335,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","keywords":["FDA","Innate Pharma","Lacutamab","S\u00e9zary syndrome","Sobi"],"articleSection":["Health Tech","International","News","Pharma"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/","name":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u3001\u30bd\u30d3\u793e\u306b\u30e9\u30af\u30bf\u30de\u30d6\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","datePublished":"2026-08-10T11:57:09+00:00","description":"\u30a4\u30cd\u30a4\u30c8\u30fb\u30d5\u30a1\u30fc\u30de\u306f\u3001T\u7d30\u80de\u30ea\u30f3\u30d1\u816b\u306e\u6cbb\u7642\u85ac\u300c\u30e9\u30af\u30bf\u30de\u30d6\u300d\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u4f9b\u4e0e\u3092\u3081\u3050\u308a\u3001\u30bd\u30d3\u793e\u3068\u6226\u7565\u7684\u63d0\u643a\u3092\u7de0\u7d50\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/08\/Innate-Pharma-Enters-Strategic-Partnership-With-Sobi-to-License-Lacutamab-in-T-cell-Lymphoma.webp","width":1200,"height":800,"caption":"Innate Pharma"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/pharma\/innate-pharma-partners-with-sobi-on-lacutamab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Partners With Sobi on Lacutamab"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/d58d81f55e8acd257ab63d49fb4ea812","name":"\u30cb\u30e5\u30fc\u30b9\u30c7\u30b9\u30af","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png74f313ad3d6fa27a1eee85c30be63d03","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","caption":"NewsDesk"},"sameAs":["https:\/\/itbusinesstoday.com"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/newsdesk\/"}]}},"authors":[{"term_id":205,"user_id":4,"is_guest":0,"slug":"newsdesk","display_name":"NewsDesk","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/it.png"},"author_category":"","first_name":"NewsDesk","last_name":"","user_url":"https:\/\/itbusinesstoday.com","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=37554"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554\/revisions"}],"predecessor-version":[{"id":37555,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/37554\/revisions\/37555"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/37592"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=37554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=37554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=37554"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=37554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}